ALU SPRAY

Indications

• Mild skin irritations
• Superficial cuts
• Allergies
• Insect bites
• Fungal infections (e.g., athlete's foot)
• Sore throat
• Hemorrhages
• Peptic ulcers
• Acne

Dosage

Children: Refer to the BNF for Children for appropriate dosing information for paediatric patients, as dosages will depend on the specific condition and formulation used.

Adults: Refer to specific product guidelines for dosage information, as aluminum formulations can vary. Generally, topical applications are used as directed for symptom relief.

Mechanism of action

Aluminum acetate acts as an astringent, causing shrinkage or constriction of body tissues following topical application. This effect occurs through osmotic flow of water away from the area of application, leading to decreased mucous secretions and blood serum discharge. Astringents like aluminum also promote mild coagulation of skin proteins, providing protective effects on the skin and aiding in the healing of minor skin irritations.

Pharmacodynamics

Aluminum compounds exert their effects primarily through their astringent properties, which can lead to reduced inflammation and secretion. The local application of aluminum results in a protective barrier on the skin and mucous membranes, which can diminish symptoms associated with irritation, such as itching or discomfort. Astringents are often indicated in conditions that require the drying of exudates or the protection of damaged skin.

Pharmacokinetics

Aluminum is poorly absorbed through the gastrointestinal tract when ingested, as most aluminum compounds are not soluble in water. When applied topically, aluminum is absorbed minimally, allowing it to act locally without significant systemic effects. The elimination of aluminum occurs primarily through the kidneys, with small amounts excreted in feces. It is important to monitor aluminum levels in patients with renal impairment, as they may be at risk of accumulation and toxicity.

Pregnancy

The safety of aluminum compounds during pregnancy has not been established. Use only if clearly needed.

Breast-feeding

Aluminum is excreted in breast milk. Caution should be exercised when administering to breastfeeding mothers.

Storage

Store in a cool, dry place, away from moisture and heat.

Formulations

• Aluminum Acetate solution
• Aluminum Hydroxide gel

Indications

• Enhanced absorption of poorly soluble drugs
• Improved therapeutic effectiveness of various medications

Dosage

Children: Refer to specific drug formulations for dosing information, as dosages can vary widely based on the active ingredient.

Adults: Refer to specific drug formulations for dosing information, as dosages can vary widely based on the active ingredient.

Mechanism of action

Micronization itself does not alter the pharmacological activity of the drug; rather, it enhances the drug's absorption characteristics. This is particularly significant for drugs that are poorly soluble, as increased absorption can lead to more effective therapeutic outcomes.

Pharmacodynamics

The pharmacodynamics of micronized drugs remain consistent with the pharmacological profile of the active ingredient. Micronized drugs often exhibit enhanced onset of action due to increased absorption rates, leading to quicker therapeutic effects. However, the specific effects will depend on the drug and its mechanism of action.

Pharmacokinetics

Micronization can significantly influence the pharmacokinetics of a drug by improving its absorption in the gastrointestinal tract. This may lead to increased peak plasma concentrations and altered time to peak effect. The elimination half-life and volume of distribution may remain unchanged, but the overall bioavailability may be improved.

Pregnancy

Micronized formulations should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Consultation with a healthcare provider is recommended.

Breast-feeding

Caution is advised when using micronized drugs while breastfeeding. The effects on the infant should be considered, and consultation with a healthcare provider is recommended.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Mechanism of action

Aluminum Acetate is an astringent. An astrignent is a chemical that tends to shrink or constrict body tissues, usually locally after topical medicinal application. The shrinkage or constriction is through osmotic flow of water (or other fluids) away from the area where the astringent was applied. Astringent medicines cause shrinkage of mucous membranes or exposed tissues and are often used internally to check discharge of blood serum or mucous secretions. This can happen with a sore throat, hemorrhages, diarrhea, or with peptic ulcers. Externally applied astringents, which cause mild coagulation of skin proteins, dry, harden, and protect the skin. Acne sufferers are often advised to use astringents if they have oily skin. Astringents also help heal stretch marks and other scars. Mild astringent solutions are used in the relief of such minor skin irritations as those resulting from superficial cuts, allergies, insect bites, or fungal infections such as athlete's foot. Excessive dietary aluminum has been proposed to be a factor contributing to several neurological disorders in humans. Six 8-week-old female Swiss Webster mice were fed for 10 wk purified diets containing 100 (control), 500 or 1000 ug aluminum/g diet. Brain and liver lipid peroxidation was determined by evaluating the production of 2-thiobarbituric acid reactive substances in brain and liver homogenates in the presence or absence of 50 uM ferrous iron. 2-Thiobarbituric acid reactive substances production in the absence of iron in brain homogenates from mice fed the 1000 ug/g diet was higher (30%) than that in the 100 ug/g control group (3.1 vs 2.4 nmol 2-thiobarbituric acid reactive substances/mg protein). The addition of ferrous iron increased 2-thiobarbituric acid reactive substances production in brain homogenates from all 3 dietary groups. The iron induced 2-thiobarbituric acid reactive substances production was 26% higher in the 1000 ug/g brain homogenates than in the 100 ug/g group (4.9 vs 3.9 nmol 2-thiobarbituric acid reactive substances/mg protein). Brain 2-thiobarbituric acid reactive substances production in the presence and absence of iron was similar between the 100 and 500 ug/g aluminum groups. 2-Thiobarbituric acid reactive substances production in liver homogenates measured either with or without iron was similar for the 3 groups. These results show that, in mice, dietary aluminum intoxication leads to increased brain 2-thiobarbituric acid reactive substance production, suggesting that enhanced lipid peroxidation may be one possible mechanism underlying the neurological damage associated with increased tissue aluminum. Evidence is presented indicating that dementias are associated with a relative insufficiency of magnesium in the brain. Such insufficiency may be attributable to low intake or retention of magnesium; high intake of a neurotoxic metal, such as aluminum, which inhibits activity of magnesium requiring enzymes; or impaired transport of magnesium and/or enhanced transport of the neurotoxic metal into brain tissue. It is proposed that Alzheimer's disease involves a defective transport process, characterized by both an abnormally high incorporation of aluminum and an abnormally low incorporation that an altered serum protein contributes to the progression of Alzheimer's disease by having a greater affinity for aluminum than for magnesium, in contrast to the normal protein, which binds magnesium better than aluminum. The altered protein crosses the blood-brain barrier more efficiently than the normal protein and competes with the normal protein in binding to brain neurons. Binding of the altered protein to the target neurons would both facilitate aluminum uptake and impede magnesium uptake. Evidence suggests that albumin is the serum protein that is altered. Aluminum is established as a neurotoxin, although the basis for its toxicity is unknown. It recently has been shown to alter the function of the blood-brain barrier, which regulates ex